Law ❯ Litigation ❯ Class Action ❯ Investor Rights

Securities Fraud

Hagens Berman Seeks Lead Plaintiff in Corcept Securities Case After FDA Setback

The push signals an early fight over claims that Corcept hid FDA doubts about its lead drug.

Corcept Investors Pressed to Seek Lead Role in Securities Suit After FDA Rebuff of Relacorilant

Jury Finds Musk Liable for Misleading Twitter Investors During 2022 Takeover

Rosen and Schall Seek Lead Plaintiff in monday.com Securities Class Action

F5 Investors Face Feb. 17 Deadline in Securities Class Action Over Alleged Breach Misstatements

Law Firms Seek Lead Plaintiffs in Ramaco Securities Case Over Brook Mine Disclosures

Investor Firms Press Ardent Health Class Action Ahead of March 9 Lead-Plaintiff Deadline

Sprouts Investors Face Jan. 26 Deadline to Seek Lead Role in Securities Class Action

Ardent Health Hit With Securities Class Action Over Receivables and Reserve Disclosures

MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

Law Firms Press Synopsys Investors Ahead of Dec. 30 Lead‑Plaintiff Deadline

DeFi Technologies Sued in Securities Class Action Filed in Eastern District of New York

Perrigo Faces Securities Class Action Over Nestlé Infant-Formula Unit After Guidance Cut

Freeport Faces Investor Class Action Over Grasberg Safety Disclosures as Firms Court Lead Plaintiff

DexCom Faces Wave of Securities Class Actions Over FDA-Faulted CGM Changes